Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 19/20 | 0.68 |
| ▸ | CA2 | P00918 | 19/20 | 0.68 |
| ▸ | CA4 | P22748 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL392166 | 0.87 | CA1 (0.62) | CA1CA2CA4CA9CA12 | |
| SCHEMBL8760294 | 0.84 | CA1 (0.77) | CA1CA2CA4CA9CA12 | |
| SCHEMBL15873682 | 0.81 | CA1 (0.45) | CA1CA2CA4CA9CA5A | |
| SCHEMBL14338090 | 0.81 | MEN1 (0.49) | CA1CA2CA4CA9CA5A | |
| SCHEMBL7481802 | 0.81 | CA1 (0.61) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL13686435 | 0.80 | CA1 (0.44) | CA1CA2CA4CA9CA5A | |
| SCHEMBL7492311 | 0.80 | CA1 (0.69) | CA1CA2CA4CA9CA12 | |
| SCHEMBL9023668 | 0.80 | CA1 (0.56) | CA1CA2CA9CA5ACA12 | |
| SCHEMBL7933999 | 0.80 | CA1 (0.73) | CA1CA2CA4CA9CA5A | |
| SCHEMBL5348269 | 0.78 | ALDH1A1 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2129224-B1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2008124450-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008073982-A2 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031346-A1 | 5,6-DIHYDRO-1H-PYRIDIN-2-ONE COMPOUNDS | HAVCR2, CCR3, C5 | CA1 3513/4885CA2 3451/4885CA4 1792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.